May-19-22 07:00PM | |
May-05-22 07:15PM | |
04:10PM | |
May-04-22 04:30PM | |
Apr-28-22 05:00PM | |
Apr-27-22 03:03PM | |
Mar-28-22 12:47PM | |
Feb-23-22 04:01PM | |
Feb-17-22 06:00PM | |
Feb-09-22 12:25PM | |
Feb-04-22 12:52PM | American City Business Journals -17.88% |
08:34AM | |
07:00AM | |
Jan-26-22 10:48AM | |
Jan-24-22 02:48PM | American City Business Journals |
Jan-21-22 05:38PM | |
Jan-19-22 09:38AM | |
Jan-18-22 02:41PM | American City Business Journals -5.47% |
Jan-02-22 04:04PM | |
Dec-08-21 11:34AM | |
Nov-10-21 06:30PM | |
Nov-03-21 10:01PM | |
06:05PM | |
04:01PM | |
Oct-27-21 05:30PM | |
Oct-23-21 06:08AM | |
Oct-20-21 03:03PM | |
Oct-15-21 12:09PM | |
Oct-14-21 04:30PM | |
Sep-21-21 12:00PM | |
Sep-17-21 10:35AM | |
Sep-07-21 08:30PM | |
Aug-18-21 03:05PM | |
Aug-10-21 06:30PM | |
Aug-05-21 10:00AM | |
Aug-03-21 01:22PM | |
07:00AM | |
Jul-30-21 12:10PM | |
12:00PM | |
11:23AM | |
Jul-29-21 12:32AM | |
Jul-28-21 08:25PM | |
04:01PM | |
Jul-26-21 04:07PM | |
Jul-23-21 03:26PM | |
Jul-21-21 04:30PM | |
Jul-01-21 04:54AM | |
Jun-30-21 07:42AM | |
Jun-21-21 08:45PM | |
Jun-08-21 03:16PM | |
May-30-21 08:26PM | |
May-12-21 04:30PM | |
May-07-21 10:25AM | |
May-06-21 09:53PM | |
May-05-21 09:30PM | |
06:15PM | |
04:01PM | |
02:45PM | |
May-04-21 07:30AM | |
Apr-29-21 09:01PM | |
Apr-28-21 12:34PM | |
Apr-25-21 02:00AM | |
Apr-20-21 04:30PM | |
Apr-16-21 10:50PM | |
02:33PM | |
Apr-13-21 08:15AM | |
Apr-06-21 06:40AM | |
Mar-23-21 07:15AM | |
Mar-18-21 04:26PM | |
09:11AM | |
Mar-17-21 01:56PM | |
Mar-12-21 10:50PM | |
Mar-11-21 01:52PM | |
Feb-23-21 02:49PM | Investor's Business Daily |
Feb-14-21 01:32PM | |
Feb-12-21 12:54AM | |
Feb-11-21 10:28AM | |
Feb-10-21 08:30PM | |
04:28PM | |
04:01PM | |
07:34AM | |
Feb-02-21 04:30PM | |
Dec-19-20 06:11PM | |
Dec-02-20 03:02PM | |
07:35AM | |
Dec-01-20 06:00PM | |
04:47AM | |
Nov-17-20 12:43PM | |
Oct-29-20 09:31AM | |
Oct-28-20 05:55PM | |
04:01PM | |
02:30PM | |
Oct-26-20 04:01PM | |
Oct-21-20 04:45PM | |
Oct-13-20 01:14PM | |
Oct-02-20 01:44PM | |
Aug-31-20 06:30PM | |
Aug-18-20 10:24AM | |
07:00AM | |
Aug-06-20 08:21PM | |
|
|
|
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Birznieks Gunther | SVP, Business Development | Mar 02 | Sale | 11.27 | 11,517 | 129,792 | 188,807 | Mar 02 09:26 PM | Polymeropoulos Mihael Hristos | President and CEO | Mar 02 | Sale | 11.15 | 29,588 | 329,945 | 1,352,766 | Mar 02 09:27 PM | Wijkstrom Joakim | SVP, Chief Marketing Officer | Mar 02 | Sale | 11.19 | 6,974 | 78,060 | 100,278 | Mar 02 09:28 PM | Williams Timothy | SVP & General Counsel | Mar 02 | Sale | 11.09 | 12,060 | 133,779 | 103,851 | Mar 02 09:29 PM | Moran Kevin Patrick | SVP, CFO & Treasurer | Mar 02 | Sale | 11.28 | 8,832 | 99,650 | 119,691 | Mar 02 09:27 PM | Moran Kevin Patrick | SVP, CFO & Treasurer | Mar 01 | Sale | 11.19 | 3,473 | 38,863 | 128,523 | Mar 02 09:27 PM | Polymeropoulos Mihael Hristos | President and CEO | Mar 01 | Sale | 11.19 | 7,508 | 84,015 | 1,382,354 | Mar 02 09:27 PM | Birznieks Gunther | SVP, Business Development | Mar 01 | Sale | 11.19 | 4,084 | 45,700 | 200,324 | Mar 02 09:26 PM | Polymeropoulos Mihael Hristos | President and CEO | Dec 01 | Option Exercise | 4.88 | 71,676 | 349,779 | 1,321,062 | Dec 02 04:31 PM | Polymeropoulos Mihael Hristos | President and CEO | Dec 01 | Sale | 16.00 | 46,200 | 739,348 | 1,274,862 | Dec 02 04:31 PM | Polymeropoulos Mihael Hristos | President and CEO | Nov 30 | Option Exercise | 4.88 | 78,324 | 382,221 | 1,299,386 | Dec 02 04:31 PM | Polymeropoulos Mihael Hristos | President and CEO | Nov 30 | Sale | 16.49 | 50,000 | 824,275 | 1,249,386 | Dec 02 04:31 PM | Jones Aranthan II | Chief Corp. Affairs Officer | Sep 15 | Option Exercise | 11.66 | 12,119 | 141,250 | 98,804 | Sep 17 08:52 AM | Jones Aranthan II | Chief Corp. Affairs Officer | Sep 15 | Sale | 16.49 | 16,824 | 277,394 | 81,980 | Sep 17 08:52 AM | Mitchell Stephen Ray | Director | Sep 09 | Option Exercise | 12.03 | 19,109 | 229,936 | 28,324 | Sep 13 04:40 PM | Mitchell Stephen Ray | Director | Sep 09 | Sale | 16.74 | 19,109 | 319,976 | 9,215 | Sep 13 04:40 PM | Wijkstrom Joakim | SVP, Chief Marketing Officer | Aug 20 | Sale | 15.39 | 3,650 | 56,190 | 74,552 | Aug 23 04:36 PM | Williams Timothy | SVP & General Counsel | Aug 16 | Sale | 16.15 | 3,715 | 59,989 | 83,211 | Aug 17 04:31 PM | Moran Kevin Patrick | SVP, CFO & Treasurer | Jul 28 | Sale | 19.24 | 2,130 | 40,973 | 99,296 | Jul 30 09:15 AM | Jones Aranthan II | Chief Corp. Affairs Officer | Jul 26 | Sale | 19.69 | 7,250 | 142,776 | 86,685 | Jul 27 04:37 PM | Chrousos Phaedra | Director | Jun 14 | Sale | 19.34 | 2,075 | 40,132 | 12,925 | Jun 15 04:42 PM |
|